A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide

The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.

Inclusion Criteria:

• Have a diagnosis of type 2 diabetes mellitus (T2DM) of at least 1-year duration currently treated with stable doses of oral antihyperglycemic medications with or without stable doses of basal or premix insulin for the last 3 months prior to screening
• Have hemoglobin A1c (HbA1c) greater than or equal to (≥) 7.5 percent (%) and less than or equal to (≤) 11.5%, both inclusive, at screening
• Have body mass index (BMI) ≥ 23 kilogram/square meter (kg/m²)

Exclusion Criteria:

• A diagnosis of type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes, or specific type of diabetes other than T2DM
• Been treated with antihyperglycemic medication like glucagon-like peptide receptor agonists (GLP-1 RA) or have a prior history of any contraindication to GLP-1 RA therapy within 3 months prior to screening or estimated glomerular filtration rate (eGFR) <15 milliliter/minute (ml/min)/1.73 square meter (m²)
• Participants have known hypersensitivity or allergy to dulaglutide or its excipients
• Participants are on systemic steroids for any period of more than 14 days
• Participants have severe gastrointestinal (GI) disease, including severe gastroparesis
• Participants have an active or untreated malignancy, except for successfully treated basal or squamous cell carcinoma